Navigation Links
Multiple disease-related research gets green light from the NIH
Date:9/16/2008

Saranac Lake, N.Y. - Stephen Smiley, Ph.D., a member of the scientific faculty at the Trudeau Institute, whose research could lead to new treatments for several common diseases, has been awarded a research grant from the National Institutes of Health (NIH) for nearly $2 million.

Dr. Smiley and members of his laboratory are working to develop treatments for a number of diseases where an abnormal activation of blood coagulation pathways causes damage to the body. The diseases include multiple sclerosis (MS), rheumatoid arthritis, transplant rejection and sepsis, a leading cause of hospital deaths. In particular, Dr. Smiley's laboratory is studying fibrin, a blood-clotting protein that frequently accumulates at high levels in diseased tissues. These high levels of fibrin are thought to clog blood vessels and cause inflammation, thereby starving tissues of oxygen and increasing the severity of disease.

With prior funding from the NIH, Dr. Smiley's laboratory collaborated with Trudeau colleague Larry Johnson to demonstrate that, despite the risks it poses, fibrin also performs critical protective functions during immune responses.

The researchers showed that fibrin deposition is essential for survival during certain infections. Specifically, they found that fibrin staunches bleeding caused by protective immune cells as they rid the body of infected cells. In addition to protecting against this collateral damage caused by the immune system itself, Drs. Smiley and Johnson also discovered that fibrin suppresses the growth of some unhealthy bacteria.

These prior studies led the scientists to hypothesize that the human body needs to maintain a careful balance of proper fibrin levels during immune responses: "Some fibrin deposition is essential for good health, while too much can be dangerous and harmful," explained Dr. Smiley.

"I'm very pleased the NIH is continuing to support Dr. Smiley's research," said David L. Woodland, Ph.D., president and director of the Trudeau Institute. "Cutting-edge research of this caliber has the potential to lead to improved treatments for people afflicted with a number of debilitating diseases, in addition to those who suffer transplant rejections."

Dr. Smiley believes that prior attempts to treat patients suffering from sepsis by removing fibrin failed because those treatments most likely removed both unhealthy and healthy fibrin. With this infusion of research funds, Dr. Smiley's laboratory will now seek to identify what exactly tips the balance between healthy and unhealthy levels of fibrin. They recently discovered that cytokines, soluble signaling molecules within the immune system, play a primary role in regulating this balance. Now they are using a variety of models and methods to delineate precisely how cytokines regulate fibrin levels.

The NIH funds will support Dr. Smiley's research efforts over a four-year period.


'/>"/>

Contact: Brian Turner
brianturner@trudeauinstitute.org
518-891-3080
Trudeau Institute
Source:Eurekalert  

Related biology news :

1. Diverse genetic abnormalities lead to NF-κB activation in multiple myeloma
2. Nicotinic receptors may be important targets for treatment of multiple addictions
3. Emphasis on conifer forests places multiple species at risk
4. For honey bee queens, multiple mating makes a difference
5. Israeli scientists identify: Genes that affect responses of multiple sclerosis patients to copaxone
6. New magnetic separation technique might detect multiple pathogens at once
7. The power of multiples: Connecting wind farms can make a more reliable - and cheaper - power source
8. Multiple species of bacteria may cause trachoma: Implications for treatment
9. Multiple resource management is focus of new technical report
10. Potential new target for multiple sclerosis therapy
11. Fast AFM probes measure multiple properties of biomolecules or materials simultaneously
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Multiple disease-related research gets green light from the NIH
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:4/13/2016)... CHICAGO , April 13, 2016  IMPOWER physicians ... are setting a new clinical standard in telehealth ... By leveraging the higi platform, IMPOWER patients can ... weight, pulse and body mass index, and, when they ... quick and convenient visit to a local retail location ...
(Date:3/31/2016)... PROVIDENCE, R.I. , March 31, 2016  Genomics ... leadership of founding CEO, Barrett Bready , M.D., ... addition, members of the original technical leadership team, including ... Vice President of Product Development, Steve Nurnberg and Vice ... have returned to the company. Dr. Bready ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... Ginkgo Bioworks , a leading organism design company ... as one of the World Economic Forum,s Technology ... companies. Ginkgo Bioworks is engineering biology to manufacture ... the nutrition, health and consumer goods sectors. The ... Fortune 500 companies to design microbes for their ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/24/2016)... Raleigh, NC (PRWEB) , ... June 24, 2016 , ... ... find the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings ... here to read it now. , Diagnostic biomarkers are signposts in the blood, ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS ... the launch of their brand, UP4™ Probiotics, into Target stores nationwide. The company, ... proud to add Target to its list of well-respected retailers. This list includes ...
Breaking Biology Technology: